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Summary In the BUPA Study, a prospective study of 22,000 men attending a screening centre in London,
serum samples were collected and stored. The concentration of beta-carotene was measured in the stored
serum samples from 271 men who were subsequently notified as having cancer and from 533 unaffected
controls, matched for age, smoking history and duration of storage of the serum samples. The mean beta-
carotene level of the cancer subjects was significantly lower than that of their matched controls (198 and
221 MgI1 respectively, P=0.007). The difference was apparent in subjects from whom blood was collected
several years before the diagnosis of the cancer, indicating that the low beta-carotene levels in the cancer
subjects were unlikely to have been simply a consequence of pre-clinical disease. Men in the top two quintiles
of serum beta-carotene had only about 60% of the risk of developing cancer compared with men in the
bottom quintile. The study was not large enough to be able to indicate with confidence the sites of cancer for
which the inverse association between serum beta-carotene and risk of cancer applied, though the association
was strongest for lung cancer. The association may be due to beta-carotene affecting the risk directly or it
may reflect an indirect association of cancer risk with some other component of vegetables or with a non-
vegetable component of diet that is itself related to vegetable consumption.
It has been suggested that beta-carotene (and other caro-
tenoids) may play a role in reducing the incidence of cancer
(Peto et al., 1981). Beta-carotene has anti-oxidant activity
(Burton & Ingold, 1984); it is an efficient quencher of singlet
oxygen (Foote, 1979). Singlet oxygen is a toxic, and possibly
cancer inducing, form of oxygen that occurs as a result of
many metabolic reactions.
There is limited evidence to suggest that beta-carotene
supplementation reduces the risks of chemically induced
tumours in animals. Since an important function of
carotenoid pigments is to protect organisms from photo-
sensitisation, and hence probably skin cancer which can
occur as a result, the administration of beta-carotene to
animals is likely to reduce the incidence of skin cancers
occurring in those animals. What is, perhaps, of greater
interest is whether the administration of beta-carotene can
reduce the incidence of cancers that are not induced by
ultraviolet light, and in particular of cancers that affect
tissues other than skin. Dorogokupla (cited by Mathews-
Roth, 1982) induced subcutaneous tumours in rats with
injections of 9,10-dimethyl-1-2-benzanthracene (DMBA) and
skin tumours in mice by the topical application of DMBA;
animals fed a diet supplemented with unlimited amounts of
red carrots developed tumours at a lower rate than did the
animals receiving the unsupplemented diet. Mathews-Roth
(1982) administered about 6.7 grams of beta-carotene per
kilogram of diet per day to mice and showed that this led to
a considerable increase in pigment accumulation in the skin
(593 mg 100 g- 1 skin) and that the induction of skin tumours
by 7,12-dimethylbenzanthracene promoted by croton oil,
was inhibited by the stored beta-carotene, there being 3.4
tumours per mouse in the beta-carotene group compared to
11.6 tumours per mouse in the control group (P<0.01).
Mathews-Roth used canthaxanthin, a carotenoid without
vitamin A activity, as a control substance. It showed no
significant anti-cancer activity. Rettura and his colleagues
(1982) found that beta-carotene (and retinyl palmitate)
reduced the growth of implanted adenocarcinoma cells.
Temple & Basu (1987) demonstrated significantly less colon
cancers, in 1,2-dimethylhydrazine treated mice given high
dose (22mgkg-1) beta-carotene compared with similarly
treated mice given a lower dose (2mgkg- I body weight).
The dietary epidemiological studies have consistently
shown that people with a relatively low intake of beta-
carotene (or total carotenoids) have a high risk of cancer,
notably lung cancer. This was found to be the case in almost
every study, most of which were retrospective but some
prospective (Stocks, 1958; Bjelke, 1975; Phillips, 1975;
MacLennan et al, 1977; Bjelke, 1978; Tuyns et al., 1978;
Cook-Mozaffari et al., 1979; Hirayama, 1979; Mettlin et al.,
1979; Gregor et al., 1980; Mettlin et al., 1981; Modan et al.,
1981; Shekelle et al., 1981; Kvale et al., 1983; Byers et al.,
1984; Hinds et al., 1984; Ziegler et al., 1984; Long-De W. et
al., 1985; Samet et al., 1985; Stehr et al., 1985; Wu et al.,
1985; Pisani et al., 1986; Kolonel et al., 1987). For lung
cancer, the results are clear-cut; the relative risk lying
between 1.5 and 2.5 among those with low estimated beta-
carotene intakes compared with those with a high intake.
For cancer of the stomach, large bowel and oesophagus, the
relative risk was about 1.5. For cancer of the larynx, bladder
and prostate, the relative risk lay between 2 and 3. Most of
the studies have been considered in an earlier review (Wald,
1982); more recent studies have been generally confirmatory.
Unlike dietary retinol, which is not an important
determinant of serum retinol levels in well nourished
populations (Willet et al.,1984a; Wald et al., 1985), dietary
beta-carotene has a strong influence on serum beta-carotene
levels (Willet et al., 1983). Since dietary beta-carotene is
inversely associated with the risk of cancer, and dietary
beta-carotene is associated with serum beta-carotene levels, it
follows that one would expect to find an inverse association
between serum beta-carotene and the risk of cancer. To see
if this was indeed the case, we conducted a prospective study
of serum beta-carotene levels in men attending a medical
screening centre in London.
Subjects and methods
The design of the prospective study has been described
before (Wald et al., 1980, 1986). In summary, blood was
collected from about 22,000 men aged 35-64 years who,
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between 1975 and 1982, attended the British United
Provident Association (BUPA) Medical Centre in London
for a comprehensive medical examination. Serum was
separated from the blood sample and stored at -40°C. The
National Health Service records of these men were flagged
and, through the assistance of the Office of Population
Censuses and Surveys, notification was received in the event
of a diagnosis of cancer or death. By April 1985, 271 men
who had provided sufficient serum for beta-carotene analysis
were identified as having developed cancer (subjects). Two
controls were selected for each of the subjects, matched on
age (within 5 years), duration of storage of the serum sample
(within 3 months), smoking habits (current smoker, ex-
smoker or life-long non-smoker) and, for current smokers,
smoking habits - type of product smoked (cigarette, cigar or
pipe), amount smoked (within 5 cigarettes per day, 2 cigars
per day or an ounce of tobacco per week) and age of
starting to smoke (within 5 years). In this way samples from
533 matched controls were identified and analysed. This was
9 less than the 'expected' 542 because serum from some of
the cases and controls was spoilt in transport prior to assay;
if a case or both controls were so affected all three were
omitted but if only one control was so affected the remaining
matched case and control were retained in the analysis. The
beta-carotene estimations were performed by high pressure
liquid chromatography (Vuilleumier et al., 1983).
Samples were tested in four separate series, two in 1981,
one in 1983 and one in 1985. Sera from subjects and their
matched controls were always assayed in the same analytical
batch without knowledge of whether they were from subjects
or from controls. The statistical analysis was based on
logarithmically transformed values of beta-carotene, their
overall distribution being approximately Gaussian after trans-
formation. All the mean values of beta-carotene presented
are transformed back from the logarithmic scale and the
standard errors given are approximate. The mean values are
adjusted for series, to take account of any changes in assay
performance between series, but the (2-sided) p-values
given for comparing these means are derived from analyses
of variance adjusting for all the variables on which the
matching of cases and controls was based. Relative risks
were estimated by logistic regression, using the method of
Breslow and Day (1980) which takes into account the factors
included in the matching.
Results
Table I shows the mean serum beta-carotene concentration
of subjects and matched controls both overall and classified
according to the site of the cancer. The mean beta-carotene
concentration for all the cancer subjects was significantly
lower than that for their controls (198 and 221 jig -1
respectively, P =0.007). Following previous practice (Wald et
al., 1987), specific cancer sites were analysed separately if 15
or more men had developed cancer at that site. Stomach
cancer (13 subjects) was also considered separately but other
sites were grouped together. There was no evidence of a
differential effect of beta-carotene according to cancer site (a
test for heterogeneity between the seven sites being non-
significant, P>0.2), but, for some of the sites, the number of
cancer subjects available for analysis was small and the
possibility of different site-specific effects cannot be
excluded. The greatest observed effects were for cancer of
the lung and stomach.
Table II shows the mean serum beta-carotene of subjects
and controls according to the interval between blood
collection and diagnosis of cancer and Table III shows, in
the same way, the data for lung cancer alone. There was no
evidence that the differences in serum beta-carotene between
cancer subjects and controls differed for the four periods
considered in the two tables. In particular, it appeared that
the difference in beta-carotene was present in subjects who
had blood collected several years before the diagnosis of
cancer. (The mean levels in both cancer subjects and controls
decreased with increasing time to diagnosis on account of
the concomitant increase in duration of storage of the
samples).
Table IV shows the number of subjects and controls and
relative risks of cancer according to the quintile of serum
beta-carotene concentration. There was a statistically signifi-
cant inverse trend in relative risk (P=0.01); the risk for
men in the highest two quintiles of serum beta-carotene was
only about 60% of the risk for men in the lowest quintile.
Table V, shows in the same way, the data for lung cancer
alone.
In the design of our study we matched subjects with
controls for age, smoking habits and duration of storage of
the serum sample. Mean beta-carotene concentrations
classified according to the age of the subject at the time of
blood collection showed no consistent pattern (Table VI).
Table VII shows the mean serum beta-carotene levels
according to smoking category. Smokers had lower beta-
carotene levels than non-smokers; the lowest beta-carotene
levels tended to occur in the heavier smokers. Table VIII
shows the mean beta-carotene levels according to duration of
storage of the serum sample. There was a general decline in
serum beta-carotene level with increasing storage time; on
average the concentration declined by - 5% per year.
Therefore, in our analysis matching for smoking habits and
duration of storage emerged as being important while
matching for age less so.
Discussion
We have shown that, as expected from the dietary studies of
Table I Mean serum beta-carotene concentrations (/tgI -) in cancer subjects and matched
controls according to site ofcancer
Numbers of Mean beta-carotene
Percentage differencea
Cancer Cancer (approximate standard
Cancer site subjects Controls subjects Controls error)
Lung 50 99 158 203 -22% (8%)
Colorectal 30 59 203 228 -11% (10%)
Stomach 13 26 180 248 -27% (17%)
Bladder 15 29 211 231 -9% (20%)
CNSb 17 34 188 208 -10% (15%)
Skin 56 107 226 234 -3% (8%)
Other 90 179 209 218 -4% (6%)
All sites 271 533 198 221 -10% (4%)
aPercentage difference=(mean in cancer subjects minus mean in controls)/mean in controls;
bCentral nervous system.430 N.J. WALD et al.
Table II Mean serum beta-carotene concentrations (ug -1) in cancer subjects and matched
controls according to interval between blood collection and diagnosis of cancer
Number of Mean beta-carotene
Percentage differencea
Cancer Cancer (approximate standard
Time to diagnosis subjects Controls subjects Controls error)
Before 1 year 90 172 222 256 -13% (7%)
1-2 years 61 121 200 218 -8% (8%)
3-4 years 61 122 185 196 -6% (7%)
5 or more years 59 118 176 202 -13% (8%)
All periods 271 533 198 221 -10% (4%)
aPercentage difference =(mean in cancer subjects minus mean in controls)/mean in controls.
Table III Mean serum beta-carotene concentrations (ug1 -) in lung cancer subjects and
matched controls according to interval between blood collection and diagnosis of cancer
Number of Mean beta-carotene
Percentage differencea
Cancer Cancer (approximate standard
Time to diagnosis subjects Controls subjects Controls error)
Before 1 year 9 17 129 235 -45% (18%)
1-2 years 12 24 209 196 +7% (29%)
3-4 years 12 24 136 199 -32% (16%)
5 or more years 17 34 160 195 -18% (14%)
All periods 50 99 158 203 -22% (8%)
aPercentage difference =(mean in cancer subjects minus mean in controls)/mean in controls.
Table IV Relative risk of cancer according to serum beta-carotene
concentration
Beta-carotene
concentration Number of
Limits Cancer
Quintile (pg l-1) subjects Controls Relative riska
1st 10-134 64 100 1.33
2nd 135-185 60 99 1.21
3rd 186-248 53 104 1.02
4th 249-350 47 116 0.81
5th 351-978 47 114 0.80
All 10-978 271 533 1.00
aRelative risks take into account the matched design of the study
and are expressed relative to the risk in the 'all' category. Test for
trend: P=0.01.
Table V Relative risk of lung cancer according to serum beta-
carotene concentration
Beta-carotene Number of
concentration
Cancer
Quintile subjects Controls Relative riska
1st (lowest) 20 18 2.00
2nd 14 27 0.93
3rd 7 19 0.68
4th 4 23 0.35
5th (highest) 5 12 0.82
All 50 99 1.00
aRelative risks take into account the matched design of the study
and are expressed relative to the risk in the 'all' category. Test for
trend: P=0.008.
Table VI Mean serum beta-carotene concentrations (pg -1) in cancer subjects and controls according to age at blood
collection
Cancer subjects Controls All
Age Number Mean beta- Number Mean beta- Number Mean beta- Approximate
(years) ofmen carotene ofmen carotene ofmen carotene standard error
35-39 10 157 23 244 33 201 19
40-44 27 194 64 217 91 210 12
45-49 49 201 83 217 132 210 10
50-54 57 206 121 214 178 211 10
55-59 63 205 140 225 203 219 9
60-64 65 192 102 227 167 213 11SERUM BETA-CAROTENE AND CANCER RISK 431
Table VII Mean serum beta-carotene concentrations (jig 1) in cancer subjects and controls according to smoking status and stated cigarette
consumption at the time of blood collection
Cancer subjects Controls AlPa
Smoking Number Mean beta- Number Mean beta- Number Mean beta- Approximate
category ofmen carotene ofmen carotene ofmen carotene standard error
Life-long non-smokers 47 242 93 261 140 255 12
Ex-smokers 88 213 175 235 263 228 8
Smokers of cigarettes alone:
1-9/day 14 257 19 243 33 249 25
10- 19/day 20 172 33 183 53 179 12
20 29/day 19 142 49 168 68 160 11
30 or more/day 25 160 43 198 68 183 14.
All 78 172 144 189 222 183 7
Other smokers 58 183 121 212 179 202 8
aFor differences between four main smoking categories, P<0.0001. For a linear trend, within smokers of cigarettes alone, according to
stated consumption per day, P=0.03.
Table VIII Mean serum beta-carotene concentrations (jigl 1) in cancer subjects and controls according to duration of storage of
the serum sample
Cancer subjects Controls Alla
Storage time Number Mean beta- Number Mean beta- Number Mean beta- Approximate
(years) ofmen carotene ofmen carotene ofmen carotene standard error
<3 26 283 50 232 76 248 15
3- 24 256 50 259 74 258 15
4 -37 198 66 238 103 223 13
5 -60 196 122 235 182 221 9
6 -38 177 72 204 110 194 11
7- 32 149 66 217 98 192 12
8- 30 203 58 199 88 200 12
>.9 24 185 49 178 73 180 13
aFor linear trend according to storage time, P<0.0001.
Table IX Summary of the prospective biochemical epidemiological studies of beta-carotene and cancer
Mean beta-
carotene
difference
(jig! ').
Approximate Cancer
mean Overall mean subjects
Number of: time to beta-carotene minus
diagnosis Plasma (P) (pg/_ ') controls Published
Sex of Site of Cancer of cancer or (approximate (approximate statistical
Study subjects cancer subjects Controls (years) serum (S) s.d.)e s.d.)e significance
Stdhelin et al. (1984) Male All 115 308 4 P 206 (131) -55 (14)d not given Willett et al. (1984a) Both All 111 210 3 5 1,126 (569)a +34 (64) P=0.63b
Nomura et al. (1985) Male S sites 284 302 5 5 263 (252)C 56 (2lI)d P = .04f Menkes et al. (1986) Both Lung 99 196 5 5 278 (234) -40 (29) p=0.001b Present study Male All 271 533 3 5 213 (I30)b -23 (9)b P =0.07b
Overall 880 1,549 -35 (7)C P=0.001
aTotal carotenids were assayed, not beta-carotene; b Values obtained from analysis of log beta-carotene; 'The overall mean across studies
was calculated as a mean of the individual mean differences, each weighted inversely according to its variance; dMean difference not adjusted for smoking; es.d based on the 25th and 75th percentiles in controls; fP value for linear trend in log odds ratio over quantiles of beta-ca-rotene. (P value adjusted for smoking is given as 0.04).
beta-carotene and cancer, there is an inverse association
between serum beta-carotene and the risk of cancer and that
the effect is present for five and more years before the
diagnosis of the cancer. The study was not large enough to
be able to indicate with confidence the sites of cancer for
which the association applied though it is of interest that the
association was strongest for lung cancer, which is consistent
with the prospective dietary studies of beta-carotene intake
(Bjelke, 1975; Shekelle et al., 1981; Kvale et al., 1983).
There are four other published prospective studies of
serum beta-carotene or total carotenoids and cancer. These
are summarised in Table IX together with our present
results. Overall the results are consistent in showing that the
average serum beta-carotene level was lower in subjects who
developed cancer than in those who did not. In one study
(Willett et al., 1984), total carotenoids were measured rather
than beta-carotene alone and showed no signifilcant
difference between cancer subjects and controls. In the
reports of two of the other studies (Stdhelin et al., 1984 and
Nomura et a!., 1985) the mean beta-carotene differences
between cancer subjects and controls were not adjusted for
smoking habit. Since smokers tend to have lower serum432 N.J. WALD et ql.
beta-carotene concentrations than non-smokers and smoking
is also associated with the risk of cancer the mean
differences between cancer subjects and controls given for
these two studies is likely to over-estimate the differences in
beta-carotene that relate, independently of smoking habit, to
the risk of cancer. Nonetheless, the results of the two
remaining studies in Table IX (Menkes et al., 1986 and the
present study) which allowed for smoking habits showed a
similar, but less marked, effect.
The observation that the inverse association between beta-
carotene and the risk of cancer persists for several years
before the diagnosis of cancer, and does not appear to show
a greater effect in those cancer cases for which the time
between blood collection and diagnosis was short, indicates
that the low beta-carotene level probably precedes the
development of cancer. The fact that, in our study, there
were only 59 men in whom a diagnosis of cancer was made
more than five years after the time of blood collection means
that we cannot completely exclude the possibility that early
cancer may itself influence serum beta-carotene levels but,
taken with the known long-term association between beta-
carotene consumption and cancer, it is unlikely. The inverse
association could arise either directly, because beta-carotene
reduces the risk of cancer, or indirectly, because beta-
carotene intake is associated with the intake of another
dietary component that affects the risk of cancer. Which of
the two explanations is the correct one should emerge from
the results of the large-scale randomised trial of beta-
carotene supplementation currently in progress among
physicians in the United States of America (Hennekens,
1986). Whatever the answer the association represents a most
interesting epidemiological clue to the link between diet and
cancer.
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